| Title |
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: subgroup analyses of the CONFIRM study
|
|---|---|
| Published in |
Journal of Neurology, June 2013
|
| DOI | 10.1007/s00415-013-6968-1 |
| Pubmed ID | |
| Authors |
Michael Hutchinson, Robert J. Fox, David H. Miller, J. Theodore Phillips, Mariko Kita, Eva Havrdova, John O’Gorman, Ray Zhang, Mark Novas, Vissia Viglietta, Katherine T. Dawson |
| Abstract |
In the phase 3, randomized, placebo-controlled and active reference (glatiramer acetate) comparator CONFIRM study in patients with relapsing-remitting multiple sclerosis, oral BG-12 (dimethyl fumarate) reduced the annualized relapse rate (ARR; primary endpoint), as well as the proportion of patients relapsed, magnetic resonance imaging lesion activity, and confirmed disability progression, compared with placebo. We investigated the clinical efficacy of BG-12 240 mg twice daily (BID) and three times daily (TID) in patient subgroups stratified according to baseline demographic and disease characteristics including gender, age, relapse history, McDonald criteria, treatment history, Expanded Disability Status Scale score, T2 lesion volume, and gadolinium-enhancing lesions. BG-12 treatment demonstrated generally consistent benefits on relapse-related outcomes across patient subgroups, reflecting the positive findings in the overall CONFIRM study population. Treatment with BG-12 BID and TID reduced the ARR and the proportion of patients relapsed at 2 years compared with placebo in all subgroups analyzed. Reductions in ARR with BG-12 BID versus placebo ranged from 34% [rate ratio 0.664 (95% confidence interval 0.422-1.043)] to 53% [0.466 (0.313-0.694)] and from 13% [0.870 (0.551-1.373)] to 67% [0.334 (0.226-0.493)] with BG-12 TID versus placebo. Treatment with glatiramer acetate reduced the ARR and the proportion of patients relapsed at 2 years compared with placebo in most patient subgroups. The results of these analyses indicate that treatment with BG-12 is effective on relapses across a broad range of patients with relapsing-remitting multiple sclerosis with varied demographic and disease characteristics. |
Mendeley readers
The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 3 | 4% |
| Austria | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 67 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 17 | 24% |
| Other | 10 | 14% |
| Researcher | 9 | 13% |
| Student > Master | 7 | 10% |
| Student > Bachelor | 6 | 8% |
| Other | 13 | 18% |
| Unknown | 10 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 33 | 46% |
| Agricultural and Biological Sciences | 7 | 10% |
| Neuroscience | 5 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Psychology | 2 | 3% |
| Other | 9 | 13% |
| Unknown | 13 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 July 2013.
All research outputs
#4,571,231
of 22,712,476 outputs
Outputs from Journal of Neurology
#1,142
of 4,454 outputs
Outputs of similar age
#39,698
of 197,445 outputs
Outputs of similar age from Journal of Neurology
#6
of 49 outputs
Altmetric has tracked 22,712,476 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,454 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,445 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.